Abstract
Preclinical data suggest that adavosertib (AD; AZD1775), a selective WEE1 inhibitor, enhances the antitumour effect of olaparib (OL), a PARP inhibitor (Lallo 2018). This expansion study (NCT02511795; Part B) examined the safety and preliminary efficacy of the recommended phase II dose (Part A; Hamilton 2019) of AD plus OL in patients (pts) with small-cell lung cancer (SCLC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
